CDK4 and familial pancreatic carcinoma: Our finding that SEMA6C-low pancreatic cancer showed increased cyclin D1 expression motivated us to test whether CDK4/6 inhibitors may have therapeutic benefits on pancreatic cancer with the downregulation of SEMA6C.